This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): rh-HSP70-PC, AG-707
Description: AG-707 (recombinant heat shock protein 70 polyvalent peptide complex) is a heat shock protein (HSP)-based vaccine that is designed to activate the immune system to target HSV-2 infection. AG-707 consists of a recombinant human HSP complexed with 32 synthetic peptides that are representative of the relevant sequences, both functionally and structurally, of various HSV-2 proteins. The vaccine contains QS-21 Stimulon adjuvant, designed to strengthen the body's immune response to a vaccine's antigen, thus making it more effective.
Pink Sheet FDA Performance Tracker: CBER Approvals
Pink Sheet US FDA, Advisory Committees Rarely Disagree
Additional information available to subscribers only: